Private Equity and Venture Capital

SAMR issues 28 administrative penalties for failing to disclose M&A deals; CAC clarifies details about data export security assessment; banks and insurance companies to support advanced manufacturing

Major overhaul of Anti-Monopoly Law; PBOC joins five central banks in BIS-led regional liquidity pool; Lawmakers expand scope of online content review

EU Commission releases guidance on updated standard clauses for GDPR-regulated parties; Xiaohongshu invests in US-based Web3 startup; Regulations on price labelling and price gouging

Draft law to boost protection against systemic risks; SPC amends rules on summary procedures, service of litigation documents, small claims, and judicial confirmation; Policymakers aim to knock down localism and unify market standards

2021 regulatory trends in China, including antitrust, data privacy, sanctions, healthcare, PE/VC, capital markets, IP, banking & finance, TMT and arbitration.

Kevin Yuan, Lucca Li and Jocelyn Chen of FenXun Partners discuss China’s efforts to support continuous financial innovation in 2021 based on steady development including taking steps to protect the security of personal data in the midst of rapid developments in finance and technology, implementing detailed rules and new initiatives related to fintech innovation, and taking clear steps to open up the financial market to the outside world.

Charles Wu and Zaiguang Lu of Han Kun Law Offices review the significant legislative developments of 2021 affecting China’s private equity and venture capital industry, and offer insights on the key trends, challenges and opportunities in the sector

The HKEX has published a consultation paper to introduce its SPAC listing regime; US-China bilateral tech investment plummets 96%; and MIIT calls on telecoms and auto companies to strengthen data protection policies.

GBA Wealth Management Connect launched; minister calls for consolidation of Chinese EV manufacturers; and China-Indonesia local currency settlement agreement implemented

Edward Tung, legal counsel for Hong Kong-based venture capital firm ORI Capital, discusses the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) and the advantage of having scientific expertise when representing healthcare and biotechnology companies.